Table 4 Scientific agreement of formulated recommendations for management of malignant pleural effusion
From: Quality assessment of the guidelines for the management of malignant pleural effusions and ascites
Recommendations | ATS, 2018 [5] | ERS, 2018 [2] | BTS, 2010 [3] | CGDTMPE, 2014 [4] | CSCO, 2018 [1] | CTS, 2009 [6] | JSPM1, 2016 [7] | JSPM2, 2016 [8] |
|---|---|---|---|---|---|---|---|---|
Known or suspected malignant pleural effusion | ||||||||
 Asymptomatic | ||||||||
  Should pleural intervention be performed? | — | — | 80~100% | 80~100% | — | — | — | — |
 Symptomatic | ||||||||
  Should pleural interventions guided by ultrasound? | — | — | 80~100% | 80~100% | — | 80~100% | — | 80~100% |
  Should large-volume thoracentesis be performed? | — | — | — | — | — | — | — | — |
IPCs or pleurodesis | ||||||||
 Expandable lung | ||||||||
  Should IPCs or chemical pleurodesis be used as first-line definitive pleural intervention? | — | 80~100% | 40~60% | 40~60% | — | 40~60% | — | 40~60% |
  Should talc poudrage or talc slurry be used? | — | 0~20% | 80~100% | 80~100% | — | 40~60% | — | — |
 Nonexpandable lung, failed pleurodesis, loculated effusion | ||||||||
  Should IPCs or chemical pleurodesis be used as first-line definitive pleural intervention? | — | 80~100% | 80~100% | 80~100% | — | — | — | — |
 Other management | ||||||||
  Should medical therapy alone or medical therapy and catheter removal be used in IPC-associated infection? | — | — | — | — | — | — | — | — |